Observational Cohort Study to Evaluate the Safety and Efficacy of Pradaxa (Dabigatran Etexilate) for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery in a Routine Clinical Setting.

Trial Profile

Observational Cohort Study to Evaluate the Safety and Efficacy of Pradaxa (Dabigatran Etexilate) for the Prevention of Venous Thromboembolism in Patients Undergoing Elective Total Hip Replacement Surgery or Total Knee Replacement Surgery in a Routine Clinical Setting.

Completed
Phase of Trial: Phase IV

Latest Information Update: 17 Oct 2014

At a glance

  • Drugs Dabigatran etexilate (Primary)
  • Indications Deep vein thrombosis; Pulmonary embolism; Thromboembolism
  • Focus Adverse reactions; Therapeutic Use
  • Acronyms PRAD-2
  • Sponsors Boehringer Ingelheim Pharmaceuticals
  • Most Recent Events

    • 06 Nov 2012 Results have been presented at the American Heart Associations Scientific Sessions according to a Boehringer Ingelheim media release.
    • 31 Oct 2012 Results will be presented at the American Heart Associations Scientific Sessions according to a Boehringer Ingelheim media release.
    • 27 Oct 2011 Trial locations added for Germany, France, Poland, Spain and Ireland asreported by ClinicalTrials.gov
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top